<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1099">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04315896</url>
  </required_header>
  <id_info>
    <org_study_id>HidroxycloroquinaCOVID19</org_study_id>
    <nct_id>NCT04315896</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)</brief_title>
  <acronym>HYDRA</acronym>
  <official_title>Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Respiratory Diseases, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Respiratory Diseases, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blinded randomized clinical trial designed to evaluate the security and efficacy of
      hydroxychloroquine as treatment for COVID-19 severe respiratory disease. The investigators
      hypothesize that a 400mg per day dose of hydroxychloroquine for 10 days will reduce all-cause
      hospital mortality in patients with severe respiratory COVID-19 disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since hydroxychloroquine is a low cost and safe anti-malaria drug that has proven effects
      against COVID-19 in vitro. The investigators aim to study the security and efficacy of this
      drug in trough a double blinded randomized clinical trial. Recruited patients with severe
      respiratory disease from COVID-19 will be randomized to an intervention group (400mg per day
      dose of hydroxychloroquine) and placebo. The investigators' main outcome will be all cause
      hospital mortality. The investigators hypothesize that a 400mg per day dose of
      hydroxychloroquine for 10 days will reduce all-cause hospital mortality in patients with
      severe respiratory COVID-19 disease. Results will be compared in an intention to treat
      analysis. All clinical, analysis and data team members will be blinded to treatment
      assignment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 14, 2020</start_date>
  <completion_date type="Anticipated">August 15, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blinded, randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Clinical practitioners and data analysts will remain blinded all through the study. Blinding will end in case the attending physician considers the patient should abandon the study or some of the exclusion/elimination criteria apply.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause hospital mortality</measure>
    <time_frame>From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days</time_frame>
    <description>incidence of all-cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days</time_frame>
    <description>Days from ER admission to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of mechanical ventilation</measure>
    <time_frame>From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days</time_frame>
    <description>need of invasive or non invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days</measure>
    <time_frame>From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days</time_frame>
    <description>28 minus days without invasive ventilation support in patients with invasive mechanical ventilation at randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3-4 adverse reaction</measure>
    <time_frame>From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days</time_frame>
    <description>Adverse Reactions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>COVID-19</condition>
  <condition>Severe Acute Respiratory Syndrome</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxychloroquine tablet 200mg every 12 hours for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>identical placebo, one tablet every 12 hours for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>hydroxychloroquine 400mg day for 10 days</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo oral tablet</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent

          2. negative pregnancy test in women

          3. COVID-19 confirmed by rtPCR in any respiratory sample.

          4. Severe COVID-19 disease defined as any from the following:

               1. Pulse oximetry less than 91% or a 3% drop from base pulse oximetry or need to
                  increase supplementary oxygen in chronic hypoxia

               2. Need for mechanical ventilation (invasive or non invasive )

               3. Sepsis/septic shock.

        Exclusion Criteria:

          1. history of anaphylactic shock to hydroxychloroquine.

          2. History of previous administration of chloroquine or hydroxychloroquine (within 1
             month)

          3. decision of attending physician by any reason.

          4. History of chronic hepatic disease (Child-Pugh B or C)

          5. History of Chronic renal disease (GFR less than 30)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Hernandez-Cárdenas, MD. MSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Respiratory Diseases - México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis-Felipe Jurado-Camacho, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Respiratory Diseases - México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ireri Thirion-Romero, MD. MSc</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Respiratory Diseases - México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sebastian Rodriguez-Llamazares, MD.MPH</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Respiratory Diseases - México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rogelio Perez-Padilla, MD. PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Respiratory Diseases - México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristobal Guadarrama, MD MSc</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Respiratory Diseases - México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joel Vasquez-Pérez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Respiratory Diseases - México</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Respiratorias, &quot;Ismael Cosío Villegas&quot;</name>
      <address>
        <city>Mexico, City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 18, 2020</study_first_submitted>
  <study_first_submitted_qc>March 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Severe acute respiratory syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>As requested by other investigators.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

